VEGF receptor signalling ? in control of vascular function
The DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Vascular endothelial growth-factor receptors (VEGFRs) regulate the cardiovascular system. VEGFR1 is required for the recruitment of haematopoietic precursors and migration of monocytes and macrophages, whereas VEGFR2 and VEGFR3 are essential for the functions of vascular endothelial and lymphendothelial cells, respectively. Recent insights have shed light onto VEGFR signal transduction and the interplay between different VEGFRs and VEGF co-receptors in development, adult physiology and disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These proteins collectively contribute to promoting angiogenic activities by influencing endothelial cell proliferation [49,53,54].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [54]
In the citing paper
“Moreover, EVs’ content also encompasses an array of growth factors such as soluble growth factors like VEGF, TGFB1, IL-8, and HGF.”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [54]
In the citing paper
“Additionally, miRNAs cargos in MSCs EVs such as miR210, miR126, miR132, and miR21 have been identified as contributors to angiogenesis [49,54].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [54]
In the citing paper
“Flt-1 is one of the main receptors of the vascular endothelial growth factor (VEGF) family widely expressed in the vascular system.33”
From CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease (2018) · cites this paper as [33]
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117 · cited 1×
“Inactivation of a single Vegfa allele in mice results in early lethality at embryonic day (E)11?12 owing to deficient endothelial-cell development and lack of vessel”
BackgroundTumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628 · cited 1×
“Inactivation of a single Vegfa allele in mice results in early lethality at embryonic day (E)11?12 owing to deficient endothelial-cell development and lack of vessel”
BackgroundVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Circulating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics & Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,615
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Cited by
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“NRP-2 performs a similar role in regulating lymphangiogenesis through its interactions with VEGFR3 (adapted from Ferrara and Adamis, 2016).”
BackgroundInfluentialDevelopment, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452
3D bioprinting of collagen to rebuild components of the human heart
Lee, A., Hudson, A. R., Shiwarski, D. J., Tashman, J. W., Hinton, T. J., Yerneni, S., Bliley, J. M., Campbell, P. G., & Feinberg, A. W. (2019) · Science · doi:10.1126/science.aav9051 · Cited by 1,782
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Endothelial Cell Migration During Angiogenesis
Lamalice, L., Le Boeuf, F., & Huot, J. (2007) · Circulation Research · doi:10.1161/01.res.0000259593.07661.1e · Cited by 1,482
PI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,461
“The VEGF ligands can bind to three type III receptor tyrosine kinases: VEGFRl/FLT1, VEGFR2/KDR, and VEGFR3/FLT4, of which VEGFR2 has the most important role in VEGF-induced angiogenesis (Ellis and Hicklin, 2008).”
Lymphangiogenesis: Molecular Mechanisms and Future Promise
Tammela, T., & Alitalo, K. (2010) · Cell · doi:10.1016/j.cell.2010.01.045 · Cited by 1,441
“VEGFR-3 can form heterodimers with VEGFR-2 upon binding of the mature, proteolytically processed forms of VEGF-C and VEGF-D, which may lead to unique combinatorial signals by the intracellular domains of the two receptors (Olsson et al., 2006) (Figure 3).”
BackgroundEphrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T. S., Bochenek, M. L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Lüthi, U., et al. (2010) · Nature · doi:10.1038/nature09002 · Cited by 1,271
Piezo1 integration of vascular architecture with physiological force
Li, J., Hou, B., Tumova, S., Muraki, K., Bruns, A., Ludlow, M. J., Sedo, A., Hyman, A. J., McKeown, L., Young, R. S., et al. (2014) · Nature · doi:10.1038/nature13701 · Cited by 1,223
Differential Roles of Macrophages in Diverse Phases of Skin Repair
Lucas, T., Waisman, A., Ranjan, R., Roes, J., Krieg, T., Müller, W., Roers, A., & Eming, S. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903356 · Cited by 1,205
“To identify factors that might mediate the accelerated vascular response and the myofibroblast differentiation in control mice, we stained wound tissue for TGF-b1, a signature mediator of myofibroblast differentiation (23), and VEGF-A, one of the most potent angiogenic mediators (24).”
BackgroundTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
“VEGFR1 is also expressed by monocytes and macrophages as well as in tumour cells 27 , and VEGFR3 is mainly present in lymphatic endothelial cells, where it regulates lymphangiogenesis 28 .”
BackgroundInfluentialHolmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.05.013 · Cited by 1,020
Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting
Jakobsson, L., Franco, C. A., Bentley, K., Collins, R. T., Ponsioen, B., Aspalter, I. M., Rosewell, I., Busse, M., Thurston, G., Medvinsky, A., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2103 · Cited by 971
“Endothelial cells express three different VEGF receptors (VEGFR”
BackgroundAngiogenesis: A Team Effort Coordinated by Notch
Phng, L.-K., & Gerhardt, H. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.015 · Cited by 832
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
David, C. J., & Manley, J. L. (2010) · Genes & Development · doi:10.1101/gad.1973010 · Cited by 814
“How does what appears to be a minor modification in VEGF result in such drastically different properties? The canonical form of VEGFA binds to VEGF receptor 1 (VEGFR1) or VEGFR2, as well as coreceptors neurophilin 1 (NRP1) and heparan sulfate proteoglycan (HSPG) (Olsson et al. 2006).”
BackgroundSuchting, S., Freitas, C., le Noble, F., Benedito, R., Bréant, C., Duarte, A., & Eichmann, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611177104 · Cited by 811
Genetic determinants of cancer metastasis
Nguyen, D. X., & Massagué, J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2101 · Cited by 801
Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype
Barnett, G. C., West, C. M. L., Dunning, A. M., Elliott, R. M., Coles, C. E., Pharoah, P. D. P., & Burnet, N. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2587 · Cited by 771
Skeletal muscle: A review of molecular structure and function, in health and disease
Mukund, K., & Subramaniam, S. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1462 · Cited by 664
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
“The biology of VEGF signalling, angiogenesis and the principles upon which anti-angiogenic therapy is based have been extensively reviewed [2, 5–8].”
BackgroundKlaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
“VEGFR2 signaling depending on the tissue context (Bruns et al., 2009; Olsson et al., 2006).”
BackgroundHypoxia: A key regulator of angiogenesis in cancer
Liao, D., & Johnson, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9066-y · Cited by 721
“HIF-1 directly activates VEGF and VEGFR-1 transcription by HRE binding, and plays a significant role during normal development and tumor formation [38, 39].”
BackgroundAstrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
Argaw, A. T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J. N., Mahase, S., Dutta, D. J., Seto, J., Kramer, E. G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60842 · Cited by 733
“VEGFR2 activates 4 pathways in endothelium (Figure 7A): PLCγ, which stimulates MEK-MAPK; Shb activation of PI3K-Akt; TSAd and Src; and p38 (39).”
BackgroundDicer Dependent MicroRNAs Regulate Gene Expression and Functions in Human Endothelial Cells
Suárez, Y., Fernández-Hernando, C., Pober, J. S., & Sessa, W. C. (2007) · Circulation Research · doi:10.1161/01.res.0000265065.26744.17 · Cited by 698
Blood–Brain Barrier Pathophysiology in Traumatic Brain Injury
Chodobski, A., Zink, B. J., & Szmydynger-Chodobska, J. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0125-x · Cited by 650
“The two major receptors that VEGFA binds to are receptor tyrosine kinases VEGFR1 (also known as Flt1) and VEGFR2 or KDR/Flk1 [113, 119].”
BackgroundMiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia
Hua, Z., Lv, Q., Ye, W., Wong, C.-K. A., Cai, G., Gu, D., Ji, Y., Zhao, C., Wang, J., Yang, B. B., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000116 · Cited by 655
“When under hypoxia stimulation, VEGF is not the only angiogenic gene up-regulated, as other angiogenic factors have been reported to be up-regulated as well [22,23].”
BackgroundLee, J.-K., Park, S.-R., Jung, B.-K., Jeon, Y.-K., Lee, Y.-S., Kim, M.-K., Kim, Y.-G., Jang, J.-Y., & Kim, C.-W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084256 · Cited by 642
“Moreover, it has been reported that VEGF is a key regulator of endothelial cell (EC) proliferation and migration [41,42].”
BackgroundVEGF and Notch in Tip and Stalk Cell Selection
Blanco, R., & Gerhardt, H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006569 · Cited by 620
“2) (Takahashi and Shibuya 2005; Olsson et al. 2006).”
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
“Under pathological conditions, the increased PLGF and VEGF-A can recruit monocytes/macrophages via VEGFR1 to cancer tissues or inflammatory lesions, and significantly induce angiogenesis (Brown et al., 2001; Murakami et al., 2008).”
BackgroundInfluentialVascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
“Inactivating mutations in the catalytic loop of the kinase domain of VEGFR3 lead to human hereditary lymphedema (Milroy’s disease) that is characterized by a chronic and disfiguring swelling of the extremities owing to defective cutaneous lymphatic vessels; VEGFR3 is the only VEGF receptor for which naturally occurrin…”
BackgroundEelen, G., de Zeeuw, P., Treps, L., Harjes, U., Wong, B. W., & Carmeliet, P. (2018) · Physiological Reviews · doi:10.1152/physrev.00001.2017 · Cited by 572
Han, Y., You, X., Xing, W., Zhang, Z., & Zou, W. (2018) · Bone Research · doi:10.1038/s41413-018-0019-6 · Cited by 576
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
“All aforementioned effects of curcumin could be replicated by treating HIMECs with the selective COX-2 inhibitor NS398 (Binion et al., 2008), which is in line with auxiliary reports that causally link PG signaling to angiogenesis in colon cancer cells (Tsujii et al., 1998), breast cancer cells (Chang et al., 2005), an…”
BackgroundInfluentialDiabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
“As noted previously, VEGF-A is a major mediator of increased retinal permeability.(142,256) Blockage of VEGF has shown to reduce vascular permeability.”
BackgroundProteoglycans in cancer biology, tumour microenvironment and angiogenesis
Iozzo, R. V., & Sanderson, R. D. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01236.x · Cited by 569
“This is interesting because the vascular abnormalities observed in the perlecan morphants are similar to those observed in VEGFA morphants [59], null mutants of VEGFR2 [60] or phospholypase C 1 [61], a downstream effector of VEGFR2 [62, 63].”
BackgroundInfluentialVascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Kowanetz, M., & Ferrara, N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1520 · Cited by 564
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
“…been thought to act predominantly on the vasculature , given that its receptors are prevalent in endothelial cells and that deletion of either VEGF or VEGFR2 results in early embryonic lethality because of impaired hematopoietic and endothelial cell development (Ferrara, 2001; Olsson et al., 2006).”
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 534
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
“Subsequent downstream VEGF-A signalling of the conventional pro-angiogenic VEGF-A xxx isoforms has been identified (reviewed in Ref”
BackgroundAn essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris
Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A. E., & D'Amore, P. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905010106 · Cited by 530
“In contrast to VEGFR1, VEGF binding to VEGFR2 leads to a robust autophosphorylation and the induction of various signaling cascades including, MAPK, PLC , Akt, and Src, critical for endothelial cell proliferation, migration, and survival (2).”
BackgroundMolecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Peach, C. J., Mignone, V. W., Arruda, M. A., Alcobia, D. C., Hill, S. J., Kilpatrick, L. E., & Woolard, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041264 · Cited by 512
“Based on both in vitro and in vivo experimental evidence, VEGFxxxa isoforms are considered to be “pro-angiogenic” as major mediators of vascular permeability, cell proliferation, survival and migration, and angiogenesis [76]; in contrast, VEGFxxxb isoforms have been reported to have “anti-angiogenic” properties [74,77…”
BackgroundBiology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
“…in the extracellular domain, a single transmembrane region, and a consensus tyrosine kinase sequence that is interrupted by a kinase-insert domain and are expressed mainly on ECs and haematopoietic cells, although a lower level of expression has been reported also in other cell types 70,71 .”
BackgroundAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
“Last, but not least, the PI3K pathway seems to be involved in endothelial cell migration [35].”
BackgroundVascular endothelial growth factors and vascular permeability
Bates, D. O. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq105 · Cited by 514
“cellular tyrosine kinase activity, recruitment of SH2 domain binding proteins, and subsequent downstream signalling through multiple common signalling pathways.(26) The link between these signalling pathways and vascular permeability regulation is, however, not so clear.”
BackgroundEndothelial von Willebrand factor regulates angiogenesis
Starke, R. D., Ferraro, F., Paschalaki, K. E., Dryden, N. H., McKinnon, T. A. J., Sutton, R. E., Payne, E. M., Haskard, D. O., Hughes, A. D., Cutler, D. F., et al. (2011) · Blood · doi:10.1182/blood-2010-01-264507 · Cited by 512
Ferretti, C., Bruni, L., Dangles-Marie, V., Pecking, A. P., & Bellet, D. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml048 · Cited by 509
Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.043 · Cited by 505
“While Ig-2 and -3 mediate VEGF-A binding, Ig-4 to -6 control receptor dimerization and Ig-7 stabilizes dimer formation (Olsson et al., 2006).”
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
Reynolds, A. R., Hart, I. R., Watson, A. R., Welti, J. C., Silva, R. G., Robinson, S. D., Da Violante, G., Gourlaouen, M., Salih, M., Jones, M. C., et al. (2009) · Nature Medicine · doi:10.1038/nm.1941 · Cited by 490
“Tumor angiogenesis is predominantly driven by vascular endothelial growth factor (VEGF), a proangiogenic growth factor expressed by many solid cancer”
VEGF-A and the Induction of Pathological Angiogenesis
Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.134925 · Cited by 474
Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms
Athar, M., Back, J. H., Kopelovich, L., Bickers, D. R., & Kim, A. L. (2009) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2009.01.018 · Cited by 462
“VEGF/VEGFR-signaling is known to target PI3K, which in turn activates Akt, leading to endothelial cell survival [73].”
BackgroundInfluentialRole and Therapeutic Potential of VEGF in the Nervous System
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., & Carmeliet, P. (2009) · Physiological Reviews · doi:10.1152/physrev.00031.2008 · Cited by 448
Integrins: masters and slaves of endocytic transport
Caswell, P. T., Vadrevu, S., & Norman, J. C. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2799 · Cited by 460
“and was subsequently found to also act as a co-receptor for both pro- and anti-angiogenic factor”
BackgroundCao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.019 · Cited by 456
Blood vessel formation and function in bone
Sivaraj, K. K., & Adams, R. H. (2016) · Development · doi:10.1242/dev.136861 · Cited by 441
“VEGFR2 (or KDR) is the main receptor for VEGFA, and signaling via this receptor triggers processes inducing cell migration, proliferation and survival in ECs (Olsson et al., 2006).”
BackgroundLee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Nishimura, S., Manabe, I., Nagasaki, M., Hosoya, Y., Yamashita, H., Fujita, H., Ohsugi, M., Tobe, K., Kadowaki, T., Nagai, R., et al. (2007) · Diabetes · doi:10.2337/db06-1749 · Cited by 440
“The fact that VEGF receptor-1 is required for the recruitment of hematopoietic precursors and the migration of monocytes and macrophages (37,38) supports this model.”
Mechanisms of Vessel Branching: Filopodia on Endothelial Tip Cells Lead the Way
De Smet, F., Segura, I., De Bock, K., Hohensinner, P. J., & Carmeliet, P. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.185165 · Cited by 397
Axon Guidance Molecules in Vascular Patterning
Adams, R. H., & Eichmann, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001875 · Cited by 405
“The relevant VEGF receptors, the tyrosine kinases VEGFR2 and VEGFR3, are presented on the EC surface and, on ligand binding, trigger downstream signaling including activation of the mitogen-activated kinase pathway, phosphoinositide Kinase-3 (PI3K) and Akt, phospholipase C g, and small GTPases such as Rac1 (Olsson et…”
BackgroundInfluentialXie, G., Wang, X., Wang, L., Wang, L., Atkinson, R. D., Kanel, G. C., Gaarde, W. A., & DeLeve, L. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.017 · Cited by 410
Regulation of angiogenesis: Wound healing as a model
EMING, S., BRACHVOGEL, B., ODORISIO, T., & KOCH, M. (2007) · Progress in Histochemistry and Cytochemistry · doi:10.1016/j.proghi.2007.06.001 · Cited by 392
Hypoxia-Independent Angiogenesis in Adipose Tissues during Cold Acclimation
Xue, Y., Petrovic, N., Cao, R., Larsson, O., Lim, S., Chen, S., Feldmann, H. M., Liang, Z., Zhu, Z., Nedergaard, J., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.009 · Cited by 384
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Uterine DCs are crucial for decidua formation during embryo implantation in mice
Plaks, V., Birnberg, T., Berkutzki, T., Sela, S., BenYashar, A., Kalchenko, V., Mor, G., Keshet, E., Dekel, N., Neeman, M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36682 · Cited by 381
Yeung, T.-L., Leung, C. S., Yip, K.-P., Au Yeung, C. L., Wong, S. T. C., & Mok, S. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2015 · Cited by 377
“VEGF-A binds to the VEGF receptor tyrosine kinases VEGFR1 and VEGFR2 on endothelial cells, leading to the formation of VEGFR homodimers or heterodimers and the induction of downstream signaling events (116).”
BackgroundVascular Permeability and Drug Delivery in Cancers
Azzi, S., Hebda, J. K., & Gavard, J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00211 · Cited by 356
“VEGF-A interacts with both VEGF-R1 and -R2, but only VEGF-R2 is directly involved in normal and pathological vascular permeability (40).”
BackgroundCritical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376
Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms
Stirban, A., Gawlowski, T., & Roden, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.11.006 · Cited by 361
“VEGFR2 represents the principal receptor for vascular endothelial growth factor signaling, which leads to vasodilatation, endothelial cell migration and proliferation [107,128,129].”
BackgroundEndothelial barrier dysfunction in septic shock
Opal, S. M., & van der Poll, T. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12331 · Cited by 353
“VEGF regulates vascular permeability through binding to VEGF receptors 1–3, which are endothelial-cell specific membrane tyrosine kinase receptors [107].”
BackgroundPotential cellular and molecular causes of hypertrophic scar formation
van der Veer, W. M., Bloemen, M. C. T., Ulrich, M. M. W., Molema, G., van Zuijlen, P. P., Middelkoop, E., & Niessen, F. B. (2009) · Burns · doi:10.1016/j.burns.2008.06.020 · Cited by 353
“VEGF is considered to be instrumental for endothelial cells to further engage in new sprout formation, as it directly affects vascular permeability and temporary fibrin matrix formation, endothelial cell migration, proliferation, and survival [161].”
BackgroundVEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
“has comparatively weak kinase activity (Koch and Claesson-Welsh, 2012; Meyer et al., 2006; Olsson et al., 2006), although some studies”
ResultCSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006082 · Cited by 359
Satchell, S. C., & Braet, F. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90601.2008 · Cited by 347
“In EnC, they activate diverse signaling pathways effecting migration, proliferation, and permeability (75).”
BackgroundAn overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350
“The expression of VEGF has also been observed following inactivation of the TP53”
BackgroundTranscriptional Control of Endothelial Cell Development
De Val, S., & Black, B. L. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.014 · Cited by 346
“Numerous studies have examined the signaling molecules involved in vasculogenesis and angiogenesis, and it is well established that vascular endothelial growth factors (VEGFs) and their receptors are critical cell nonautonomous regulators of endothelial cell and blood vessel formation (Ferrara, 2004; Olsson et al., 20…”
BackgroundVEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 327
“Despite the fact that VEGF binds to VEGFR1 with ~ 10-fold higher affinity than VEGFR2, it is mainly VEGFR2 that mediates VEGF signaling in endothelial cells [39, 40].”
BackgroundPandey, A. K., Singhi, E. K., Arroyo, J. P., Ikizler, T. A., Gould, E. R., Brown, J., Beckman, J. A., Harrison, D. G., & Moslehi, J. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10271 · Cited by 338
“VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.”
BackgroundInfluentialModi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
Chen, T. T., Luque, A., Lee, S., Anderson, S. M., Segura, T., & Iruela-Arispe, M. L. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200906044 · Cited by 320
“Notably, the responses of endothelial cells to VEGF are regulated by the nature, frequency, and distribution of other receptors and interacting molecules (Soker et al., 1998; Bazzoni and Dejana, 2004; Reynolds et al., 2004; Ashikari-Hada et al., 2005; Olsson et al., 2006).”
BackgroundAmino Acid Restriction Triggers Angiogenesis via GCN2/ATF4 Regulation of VEGF and H2S Production
Longchamp, A., Mirabella, T., Arduini, A., MacArthur, M. R., Das, A., Treviño-Villarreal, J. H., Hine, C., Ben-Sahra, I., Knudsen, N. H., Brace, L. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.001 · Cited by 325
“…signal transduction via the PI3K andmitogen-activated protein kinase (MAPK) pathways involving critical second messengers nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) and changes in gene expression facilitating EC migration, proliferation, and vessel formation (Olsson et al., 2006).”
BackgroundHolderfield, M. T., & Hughes, C. C. W. (2008) · Circulation Research · doi:10.1161/circresaha.107.167171 · Cited by 320
Comprehensive characterization of the Published Kinase Inhibitor Set
Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323
Role of hypoxia-induced exosomes in tumor biology
Shao, C., Yang, F., Miao, S., Liu, W., Wang, C., Shu, Y., & Shen, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0869-y · Cited by 317
Mourad, J.-J., des Guetz, G., Debbabi, H., & Levy, B. I. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm550 · Cited by 306
“Nitric oxide (NO) generation is therefore an essential component of the response pattern to angiogenic growth factors [15]; thus VEGF blockade and NO inhibition could result in several common abnormalities.”
BackgroundThe impact of VEGF on cancer metastasis and systemic disease
Yang, Y., & Cao, Y. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.011 · Cited by 286
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304
Coon, B. G., Baeyens, N., Han, J., Budatha, M., Ross, T. D., Fang, J. S., Yun, S., Thomas, J.-L., & Schwartz, M. A. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201408103 · Cited by 299
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Shen, Y. H., Shoichet, M. S., & Radisic, M. (2008) · Acta Biomaterialia · doi:10.1016/j.actbio.2007.12.011 · Cited by 289
Simó, R., Sundstrom, J. M., & Antonetti, D. A. (2014) · Diabetes Care · doi:10.2337/dc13-2002 · Cited by 280
“Finally, VEGFR-3 is a critical regulator of developmental and adult vasculogenesis and lymphangiogenesis (6,14).”
Background(1926) · The American Journal of Surgery · doi:10.1016/s0002-9610(26)90068-8 · Cited by 293
Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain
Hamilton, J. L., Nagao, M., Levine, B. R., Chen, D., Olsen, B. R., & Im, H.-J. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2828 · Cited by 287
“(9,10) Murine counterparts of human VEGF include VEGF120, VEGF164, VEGF188, and VEGF205.”
BackgroundInfluentialHeparan Sulfate in trans Potentiates VEGFR-Mediated Angiogenesis
Jakobsson, L., Kreuger, J., Holmborn, K., Lundin, L., Eriksson, I., Kjellén, L., & Claesson-Welsh, L. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.03.009 · Cited by 274
Self-citationNeuropilin-1/GIPC1 Signaling Regulates α5β1 Integrin Traffic and Function in Endothelial Cells
Valdembri, D., Caswell, P. T., Anderson, K. I., Schwarz, J. P., König, I., Astanina, E., Caccavari, F., Norman, J. C., Humphries, M. J., Bussolino, F., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000025 · Cited by 271
“Through its b1-b2 domains, Nrp1 binds and potentiates the proangiogenic activity of VEGF-A165, which contains the heparin-binding peptide encoded by exon 7 [13].”
BackgroundGastrointestinal radiation injury: Symptoms, risk factors and mechanisms
Shadad, A. K. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i2.185 · Cited by 273
VEGF receptor protein–tyrosine kinases: Structure and regulation
Roskoski, R. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.121 · Cited by 269
Cytokines, IBD, and Colitis-associated Cancer
Francescone, R., Hou, V., & Grivennikov, S. I. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000236 · Cited by 272
“and PI3K, stimulating endothelial cell proliferation and migration.(89) Although angiogenesis is an important part of the wound healing process, overamplification of revascularization can promote both IBD and CAC.”
BackgroundNanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M., Dorresteijn, B., Oliveira, S., & van Bergen en Henegouwen, P. M. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 265
“This receptor has been described to be overexpressed in many types of cancers, among which include lung and colon cancers [25] .”
Metadata
- Authors
- Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L.
- Affiliations
- Uppsala University (SE)
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2006-05
- Volume
- 7
- Issue
- 5
- Pages
- 359-371
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W2091774189
- Cited by
- 3,122
- References
- 141
- Citations by year
- 2026: 88 · 2025: 107 · 2024: 116 · 2023: 127 · 2022: 127 · 2021: 158 · 2020: 160 · 2019: 156 · 2018: 156 · 2017: 176 · 2016: 202 · 2015: 184 · 2014: 212 · 2013: 231 · 2012: 190
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vetenskapsrådet
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Axon Guidance and Neuronal Signaling
- Keywords
- VEGF receptors, VEGF signaling, VEGFR1, VEGFR2, VEGFR-3, angiogenesis, pathological angiogenesis, vascular development, endothelial cells, signal transduction, anti-angiogenic cancer therapy
- MeSH terms
- Animals, Humans, Stem Cells, Signal Transduction, Neovascularization, Physiologic, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Embryonic Development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.